Subsequent studies analyzing molecular alterations in the tumors of lung cancer patients who had an excellent response to EGFR TKIs revealed the presence of unique mutations in EGFR that conferred high sensitivity to EGFR TKIs [7,8,9]. This evidence concerns the gene EGFR and lung cancer.